Preview

Вопросы современной педиатрии

Расширенный поиск

ДЕЗЛОРАТАДИН В ЛЕЧЕНИИ АЛЛЕРГИЧЕСКОГО РИНИТА: РЕЗУЛЬТАТЫ РАНДОМИЗИРОВАННЫХ, ПЛАЦЕБОКОНТРОЛИРУЕМЫХ ИССЛЕДОВАНИЙ

Аннотация

В обзоре литературы представлены результаты рандомизированных плацебо-контролируемых исследований, направленных на изучение эффективности современного неседативного антигистаминного препарата дезлоратадина при аллергическом рините (АР). Доказано, что применение дезлоратадина сопровождается достоверным уменьшением по сравнению с плацебо суммарного индекса симптомов АР, индекса назальных симптомов, улучшением назальной проходимости. Установлено преимущество дезлоратадина над плацебо в снижении числа эозинофилов в смывах со слизистой оболочки носа. Имеющиеся данные свидетельствуют о том, что эффективность дезлоратадина при АР соответствует уровню доказательности Ia.
Ключевые слова: дезлоратадин, аллергический ринит, рандомизированные плацебо-контролируемые исследования.
(Вопросы современной педиатрии. – 2008; 7(1):82-90)

Об авторе

Р.Т. Сайгитов
Научный центр здоровья детей РАМН, Москва
Россия


Список литературы

1. Plaut M., Valentine M. Clinical practice. Allergic rhinitis. N. Engl. J. Med. 2005; 353: 1934–1944.

2. ISAAC Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet. 1998; 351 (9111): 1225–1232.

3. Galassi C., De Sario M., Biggeri A. et al. Changes in prevalence of asthma and allergies among children and adolescents in Italy: 1994–2002. Pediatrics. 2006; 117 (1): 34–42.

4. Сватко Л.Г., Маланичева Т.Г., Рафаилов В.В. и др. Эпидемиология и особенности течения аллергического ринита у детей. Вестник оториноларингологии. 2004; 4: 7–8.

5. Blaiss M. Allergic Rhinitis in Schoolchildren Consensus Group. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr. Med. Res. Opin. 2004; 20 (12): 1937–1952.

6. Bousquet J., Gaugris S., Kocevar V. et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy. Clin. Exp. Allergy. 2005; 35 (6): 723–727.

7. GA2LEN: allergy & asthma, 2006. URL: http://www.ga2len.net.

8. Canonica G. Introduction to nasal and pulmonary allergy cascade. Allergy. 2002; 57 (75): 8–12.

9. Bousquet J., Van Cauwenberge P., Khaltaev N. ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J. Allergy. Clin. Immunol. 2001; 108 (5): 147–334.

10. Demoly P., Allaert F., Lecasble M. et al. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy. 2003; 58 (7): 672–675.

11. Demoly P., Allaert F., Lecasble M. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002; 57 (6): 546–554.

12. Bachert C., van Cauwenberge P., Olbrecht J. et al. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy. 2006; 61 (6): 693–698.

13. Bousquet J., Van Cauwenberge P., Bachert C. et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI). Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2003; 58 (3): 192–197.

14. Bousquet J., van Cauwenberge P., Ait Khaled N. et al. Pharmacologic and anti–IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy. 2006; 61 (9): 1086–1096.

15. Léger D., Annesi-Maesano I., Carat F. et al. Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch. Intern. Med. 2006; 166 (16): 1744–1748.

16. Ng K., Chong D., Wong C. et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics. 2004; 113 (2): 116–121.

17. Vuurman E., Van Veggel L., Uiterwijk M. et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann. Allergy. 1993; 71 (2): 121–126.

18. Vermeulen J., Mercer M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Pediatr. Allergy. Immunol. 1994; 5 (4): 209–213.

19. Desloratadine (AERIUS). Prescribing information. Kenilworth, N.J. USA: Schering Plough Corporation. 2005. P. 1–7.

20. Wilken J., Daly A., Sullivan C. et al. Desloratadine for allergic rhinitis. Exp. Rev. Clin. Immunol. 2006; 2: 209–224.

21. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy. 2001; 56 (65): 14–20.

22. Shekelle P., Woolf S., Eccles M. et al. Clinical guidelines: developing guidelines. BMJ. 1999; 318 (7183): 593–596.

23. Penagos M., Compalati E., Tarantini F. et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta–analysis of randomized, placebo controlled, double blind trials. Ann. Allergy Asthma Immunol. 2006; 97 (2): 141–148.

24. Rodrigo G., Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann. Allergy Asthma Immunol. 2006; 96 (6): 779–786.

25. Canonica G., Tarantini F., Compalati E. et al. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007; 62 (4): 359–366.

26. Robinson K., Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using. Med. Int. J. Epidemiol. 2002; 31 (1): 150–153.

27. Dawson B. Research questions about one group. Dawson B. editor. In: Basic and clinical biostatistics. 4th ed. Philadelphia: McGraw–Hill Medical. 2004. 118 р.

28. Alderson P., Green S. Cochrane Collaboration open learning material for reviewers. Version 1.1. 2002. URL: http://www.cochrane.org.

29. Jadad A., Moore R., Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials. 1996; 17 (1): 1–12.

30. Moher D., Cook D., Jadad A. et al. Assessing the quality of randomized controlled trials: implications for the conduct of meta-analyses. Health Technol. Assess. 1999; 3 (12): 12.

31. Moher D., Jadad A., Nichol G. et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin. Trials. 1995; 16 (1): 62–73.

32. Deeks J., Altman D., Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta–analysis. Ed.: Egger M., Davey Smith G., Altman D.G. In: Systematic reviews in health care. London: BMJ Publishing. 2001. P. 285–312.

33. Higgins J., Thompson S., Deeks J. et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327 (7414): 557–560.

34. Der Simonian R., Laird N. Meta–analysis in clinical trials. Control Clin. Trials. 1986; 7 (3): 177–188.

35. Ciprandi G., Cirillo I., Vizzaccaro A. et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int. Immunopharmacol. 2005; 5 (13–14): 1800–1808.

36. Ciprandi G., Cirillo I., Vizzaccaro A. Et al. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin. Exp. Allergy. 2004; 34 (6): 958–964.

37. Cyr M., Hayes L., Crawford L. et al. The effect of desloratadine on eosinophil basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. Int. Arch. Allergy Immunol. 2005; 138 (3): 209–216.

38. Deruaz C., Leimgruber A., Berney M. et al. Levocetirizine better protects than desloratadine in a nasal provocation with allergen. J. Allergy Clin. Immunol. 2004; 113 (4): 669–676.

39. Horak F., Stubner P., Zieglmeyer R. et al. Comparison of the effects of desloratadine 5 mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy. 2003; 58 (6): 481–485.

40. Horak F., Stubner P., Zieglmeyer R. et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen induced allergic rhinitis in an allergenexposure unit. J. Allergy Clin. Immunol. 2002; 109 (6): 956–961.

41. Kim K., Sussman G., Hebert J. et al. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 2006; 96 (3): 460–465.

42. Lee D., Gardiner M., Haggart K. et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin. Exp. Allergy. 2004; 34 (4): 650–653.

43. Meltzer E., Prenner B., Nayak A. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin. Drug. Invest. 2001; 21: 25–32.

44. Meltzer E., Jalowayski A., Vogt K. et al. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann. Allergy Asthma Immunol. 2006; 96 (4): 363–368.

45. Passalacqua G., Guerra L., Compalati E. et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int. Arch. Allergy Immunol. 2004; 135 (2): 143–147.

46. Simons F., Prenner B., Finn A. Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J. Allergy Clin. Immunol. 2003; 111 (3): 617–622.

47. Wilson A., Haggart K., Sims E. et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin. Exp. Allergy. 2002; 32 (10): 1504–1509.

48. Van Cauwenberge P., Bachert C., Passalacqua G. et al. Consensus statement on the treatment of allergic rhinitis (European Academy of Allergology and Clinical Immunology). Allergy. 2000; 55: 116–134.

49. AERIUS. European Public Assessment Reports (EPARs) on products given a marketing authorization via the centralized procedure.

50. URL: http://www.emea.eu.int/htms/human/epar/afepar.htm.

51. Gupta S., Kantesaria B., Banfield C. et al. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br. J. Clin. Pharmacol. 2007; 64 (2): 174–184.

52. Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr. Med. Res. Opin. 2004; 20 (12): 1959–1965.

53. Prenner B, Ballona R, Bueso A, et al. Safety of desloratadine syrup in children six months to younger than 2 years of age: a randomized, double blinded, placebo controlled study. Pediatric Asthma Allergy Immunology. 2006; 19 (2): 91–99.

54. Banfield C., Hunt T., Reyderman L. et al. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin. Pharmacokinet. 2002; 41 (Suppl. 1): 29–35.

55. Banfield C., Gupta S., Marino M. et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin. Pharmacokinet. 2002; 41 (4): 311–318.

56. Stoltz M., Arumugham T., Lippert C. et al. Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A). Biopharm. Drug Dispos. 1997; 18 (7): 645–648.

57. Warner J. Early treatment of theatopic child. Pediatr. Allergy Immunol. 1997; 8 (10): 46–48.

58. Iikura Y., Naspitz C., Mikawa H. et al. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann. Allergy. 1992; 68 (3): 233–236.

59. Bustos G., Bustos D., Bustos G. et al. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin. Exp. Allergy. 1995; 25 (6): 568–573.

60. Fuhlbrigge A., Adams R. The effect of treatment of allergic rhinitis on asthma morbidity, including emergency department visits. Curr. Opin. Allergy Clin. Immunol. 2003; 3 (1): 29–32.

61. Berger W., Schenkel E., Mansfield L. Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann. Allergy. Asthma. Immunol. 2002; 89 (5): 485–491.

62. Baena-Cagnani C., Berger W., Du Buske L. et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2 agonists in patients with seasonal allergic rhinitis and asthma. Int. Arch. Allergy. Immunol. 2003; 130 (4): 307–313.

63. Corren J., Manning B., Thompson S. et al. Rhinitis therapy and the prevention of hospital care for asthma: a case control study. J. Allergy. Clin. Immunol. 2004; 113 (3): 415–419.


Для цитирования:


Сайгитов Р. ДЕЗЛОРАТАДИН В ЛЕЧЕНИИ АЛЛЕРГИЧЕСКОГО РИНИТА: РЕЗУЛЬТАТЫ РАНДОМИЗИРОВАННЫХ, ПЛАЦЕБОКОНТРОЛИРУЕМЫХ ИССЛЕДОВАНИЙ. Вопросы современной педиатрии. 2008;7(1):82-90.

For citation:


Saygitov R. DESLORATADINE IN TREATMENT OF ALLERGIC RHINITIS: RESULTS OF RANDOMIZED, PLACEBO_CONTROLLED TRIAL. Current Pediatrics. 2008;7(1):82-90. (In Russ.)

Просмотров: 509


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)